Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S31-S45 , December 2006

What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting?

  • Fritz Jänicke (Professor; Chairman and Head of the Department of Gynecology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 40 4 28 03 3510; Fax: +49 40 4 28 03 4355.
  • Paolo Pronzato (Professor)

      Affiliations

    • Tel.: +39 0187 533 688; Fax: +39 0187 533 688.
    • Present Address: Department of Oncology, Istituto Nazionale per la Ricerca sul Cancro, largo R.Benzi 10, 10632 Genova. Tel.: +39 010 5600668; Fax +39 010 5600850.

References 

  1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–1717
  2. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology. 2005;16:1569–1583
  3. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. Journal of the National Comprehensive Cancer Network. 2005;3:309–314
  4. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology. 2005;23:619–629
  5. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139Erratum in: Lancet 2002; 360: 1520
  6. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  7. Thürlimann B on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine. 2005;353:2747–2756
  8. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology. 2005;23:5138–5147
  9. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England Journal of Medicine. 2004;350:1081–1092Erratum in: The New England Journal of Medicine 2004; 351: 2461
  10. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  11. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology. 1996;14:2738–2746
  12. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 13)
  13. Rea D. Phase III randomized study of adjuvant exemestane versus tamoxifen in postmenopausal women with early breast cancer. Protocol CRC-TU-TEAM. Available at http://clinicaltrial.gov/ct/show/NCT00032136;jsessionid=1D44C3F4F6552E508917E7B85DFF2E38?order=46Accessed 11 July 2006
  14. Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG trial 8 and the ITA trial. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 18)
  15. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. British Journal of Cancer. 2006;94:460–464
  16. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 2005;97:1262–1271
  17. Arimidex Prescribing Information. www.arimidex.com. Accessed 11 July 2006.
  18. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine. 2003;18:937–947
  19. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001;11:95–102
  20. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101:1311–1322
  21. Brufsky A, Harker W, Beck J, et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Journal of Clinical Oncology. 2005;23:12s;(abstract 533)
  22. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). European Journal of Cancer Supplements. 2006;4:48;(abstract 12)
  23. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology. 2003;30:763–775
  24. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. Journal of Clinical Oncology. 2004;22:4261–4271
  25. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology. 2006;24:910–917
  26. McArthur HL, Olivotto I, Gelmon KA, et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Research and Treatment. 2005;94:(abstract 3001)
  27. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology. 2001;19:3808–3816
  28. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology. 2005;23:7512–7517
  29. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 44)
  30. Locker GY, on behalf of the ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. 27th Annual San Antonio Breast Cancer Symposium, 8–11 December 2004 (abstract 2085).
  31. Delea TE, Karnon J, Thomas SK, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Research and Treatment. 2005;94:(abstract 2054)
  32. Karnon J, Delea TE, Barghout V, et al. Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 2058)
  33. Risebrough NA, Verma S, Trudeau M, et al. Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 2050)
  34. Thompson D, Taylor DCA, Montoya EL, et al. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 5037)

PII: S1521-690X(06)00080-7

doi: 10.1016/j.beem.2006.10.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S31-S45 , December 2006

Article Tools

* Image Usage & Resolution